Table 2.
Predictors (Visit 1) of Carotid Artery Plaque (at Visit 4)
| Variable | OR (95% CI) | P Value |
|---|---|---|
| “Best” clinical model | ||
| Age (per 5 y) | 1.26 (1.06–1.49) | 0.007 |
| Smoking (active) | 1.79 (1.23–2.60) | 0.002 |
| LDL‐C, g/L | 1.72 (1.10–2.69) | 0.018 |
| PCSK9 plus LDLR on top of the “best” clinical model | ||
| PCSK9 (NPX) | 2.14 (1.28–3.58) | 0.004 |
| LDLR (NPX) | 0.91 (0.66–1.25) | 0.57 |
| rs562556 polymorphism on top of the “best” clinical model plus PCSK9 and LDLR proteins | ||
| rs562556 (risk per A allele) | 1.60 (1.10–2.32) | 0.014 |
| PCSK9/LDLR ratio on top of the “best” clinical model | ||
| PCSK9/LDLR (ratio) | 1.32 (1.04–1.67) | 0.023 |
N=997; N. Plaque=203. Median time between visit 1 and visit 4 , 18.5 years. Our models presented good fit: Hosmer –Lemeshow goodness‐of‐fit test P>0.5 for all models (ie, clinical alone and clinical plus biomarkers). LDL‐C indicates low‐density lipoprotein cholesterol; LDLR, low‐density lipoprotein receptor; NPX, Olink log2 normalized protein expression; OR, odds ratio; PCSK9, proprotein convertase subtilisin/kexin type 9.